HER2 discordance between primary and metastatic breast cancer: Assessing the clinical impact

Cancer Treatment Reviews

Volumn 39, Issue 8, 2013, Pages 947-957

  Turner, Natalie H ^a   Di Leo, Angelo ^a  

^a ISTITUTO TOSCANO TUMORI   (Italy)

Author keywords

Breast cancer; Discordance; HER2; Prognosis; Rebiopsy; Recurrence; Trastuzumab

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TRASTUZUMAB;

BREAST CANCER; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; DISEASE FREE SURVIVAL; FEMALE; HUMAN; OVERALL SURVIVAL; PHENOTYPE; PROGNOSIS; PROTEIN DEPLETION; QUALITATIVE RESEARCH; REVIEW; TREATMENT FAILURE;

EID: 84883551114     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2013.05.003     Document Type: Review

References (54)

1. Cardoso F., Costa A., Norton L., et al. 1st International consensus guidelines for advanced breast cancer (ABC 1). Breast 2012, 21:242-252.
2. Houssami N., Macaskill P., Balleine R.L., et al. HER2 discordance between primary breast cancer and its paired metastasis: tumor biology or test artefact? Insights through meta-analysis. Breast Cancer Res Treat 2011, 129:659-674.
3. Amir E., Miller N., Geddie W., et al. Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer. J Clin Oncol 2012, 30:587-592.
4. Bogina G., Bortesi L., Marconi M., et al. Comparison of hormonal receptor and HER-2 status between breast primary tumors and relapsing tumors: clinical implications of progesterone receptor loss. Virchows Arch 2011, 459:1-10.
5. Botteri E., Disalvatore D., Curigliano G., et al. Biopsy of liver metastasis for women with breast cancer: impact on survival. Breast 2012, 21:284-288.
6. Chang H.J., Han S.W., Oh D.Y., et al. Discordant human epidermal growth factor receptor 2 and hormone receptor status in primary and metastatic breast cancer and response to trastuzumab. Jpn J Clin Oncol 2011, 41:593-599.
7. Curigliano G., Bagnardi V., Viale G., et al. Should liver metastases of breast cancer be biopsied to improve treatment choice?. Ann Oncol 2011, 22:2227-2233.
8. Dieci M.V., Barbieri E., Piacentini F., et al. Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single-institution analysis. Ann Oncol 2013, 24(1):101-108.
9. Duchnowska R., Dziadziuszko R., Trojanowski T., et al. Conversion of epidermal growth factor receptor 2 and hormone receptor expression in breast cancer metastases to the brain. Breast Cancer Res 2012, 14:R119.
10. Fabi A., Di Benedetto A., Metro G., et al. HER2 protein and gene variation between primary and metastatic breast cancer: significance and impact on patient care. Clin Cancer Res 2011, 17:2055-2064.
11. Hoefnagel L.D., Van de Vijver M.J., Van Slooten H.J., et al. Receptor conversion in distant breast cancer metastases. Breast Cancer Res 2010, 12:R75.
12. Jensen J.D., Knoop A., Ewertz M., et al. ER, HER2, and TOP2A expression in primary tumor, synchronous axillary nodes, and asynchronous metastases in breast cancer. Breast Cancer Res Treat 2012, 132:511-521.
13. Lindstrom L.S., Karlsson E., Wilking U.M., et al. Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. J Clin Oncol 2012, 30:2601-2608.
14. Liu J., Deng H., Jia W., et al. Comparison of ER/PR and HER2 statuses in primary and paired liver metastatic sites of breast carcinoma in patients with or without treatment. J Cancer Res Clin Oncol 2012, 138:837-842.
15. Macfarlane R., Seal M., Speers C., et al. Molecular alterations between the primary breast cancer and the subsequent locoregional/metastatic tumor. Oncologist 2012, 17:172-178.
16. Montagna E., Bagnardi V., Rotmensz N., et al. Breast cancer subtypes and outcome after local and regional relapse. Ann Oncol 2012, 23:324-331.
17. Niikura N., Liu J., Hayashi N., et al. Loss of human epidermal growth factor receptor 2 (HER2) expressions in metastatic sites of HER2-overexpressing primary breast tumors. J Clin Oncol 2012, 30:593-599.
18. Nishimura R., Osako T., Okumura Y., et al. Changes in the ER, PgR, HER2, p53 and Ki-67 biological markers between primary and recurrent breast cancer: discordance rates and prognosis. World J Surg Oncol 2011, 9:131.
19. Sari E., Guler G., Hayran M., et al. Comparative study of the immunohistochemical detection of hormone receptor status and HER-2 expression in primary and paired recurrent/metastatic lesions of patients with breast cancer. Med Oncol 2011, 28:57-63.
20. St Romain P., Madan R., Tawfik O.W., et al. Organotropism and prognostic marker discordance in distant metastases of breast carcinoma: fact or fiction? A clinicopathologic analysis. Hum Pathol 2012, 43:398-404.
21. Thompson A.M., Jordan L.B., Quinlan P., et al. Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence in Tissues Study (BRITS). Breast Cancer Res 2010, 12:R92.
22. Wilking U., Karlsson E., Skoog L., et al. HER2 status in a population-derived breast cancer cohort: discordances during tumor progression. Breast Cancer Res Treat 2011, 125:553-561.
23. Xiao C., Gong Y., Han E.Y., et al. Stability of HER2-positive status in breast carcinoma: a comparison between primary and paired metastatic tumors with regard to the possible impact of intervening trastuzumab treatment. Ann Oncol 2011, 22:1547-1553.
24. Perez E.A., Suman V.J., Davidson N.E., et al. HER2 testing by local, central, and reference laboratories in specimens from the North central cancer treatment group N9831 intergroup adjuvant trial. J Clin Oncol 2006, 24:3032-3038.
25. Wolff A.C., Hammond M.E., Schwartz J.N., et al. American society of clinical oncology/college of American pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007, 25:118-145.
26. Zidan J., Dashkovsky I., Stayerman C., et al. Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease. Br J Cancer 2005, 93:552-556.
27. Pusztai L., Viale G., Kelly C.M., et al. Estrogen and HER-2 receptor discordance between primary breast cancer and metastasis. Oncologist 2010, 15:1164-1168.
28. Sekido Y., Umemura S., Takekoshi S., et al. Heterogeneous gene alterations in primary breast cancer contribute to discordance between primary and asynchronous metastatic/recurrent sites: HER2 gene amplification and p53 mutation. Int J Oncol 2003, 22:1225-1232.
29. Symmans W.F., Liu J., Knowles D.M., et al. Breast cancer heterogeneity: evaluation of clonality in primary and metastatic lesions. Hum Pathol 1995, 26:210-216.
30. Lower E.E., Glass E.L., Bradley D.A., et al. Impact of metastatic estrogen receptor and progesterone receptor status on survival. Breast Cancer Res Treat 2005, 90:65-70.
31. Kuukasjarvi T., Kononen J., Helin H., et al. Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy. J Clin Oncol 1996, 14:2584-2589.
32. Johnston S.R., Saccani-Jotti G., Smith I.E., et al. Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer. Cancer Res 1995, 55:3331-3338.
33. Van de Ven S., Smit V.T., Dekker T.J., et al. Discordances in ER, PR and HER2 receptors after neoadjuvant chemotherapy in breast cancer. Cancer Treat Rev 2011, 37:422-430.
34. Gong Y., Booser D.J., Sneige N. Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma. Cancer 2005, 103:1763-1769.
35. Lower E.E., Glass E., Blau R., et al. HER-2/neu expression in primary and metastatic breast cancer. Breast Cancer Res Treat 2009, 113:301-306.
36. Falck A.K., Ferno M., Bendahl P.O., et al. Does analysis of biomarkers in tumor cells in lymph node metastases give additional prognostic information in primary breast cancer?. World J Surg 2010, 34:1434-1441.
37. Liedtke C., Broglio K., Moulder S., et al. Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer. Ann Oncol 2009, 20:1953-1958.
38. Simmons C., Miller N., Geddie W., et al. Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases?. Ann Oncol 2009, 20:1499-1504.
39. Guarneri V., Giovannelli S., Ficarra G., et al. Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management. Oncologist 2008, 13:838-844.
40. Chung Y.L., Sheu M.L., Yang S.C., et al. Resistance to tamoxifen-induced apoptosis is associated with direct interaction between Her2/neu and cell membrane estrogen receptor in breast cancer. Int J Cancer 2002, 97:306-312.
41. Pietras R.J., Arboleda J., Reese D.M., et al. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 1995, 10:2435-2446.
42. Yang Z., Barnes C.J., Kumar R. Human epidermal growth factor receptor 2 status modulates subcellular localization of and interaction with estrogen receptor alpha in breast cancer cells. Clin Cancer Res 2004, 10:3621-3628.
43. Shou J., Massarweh S., Osborne C.K., et al. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 2004, 96:926-935.
44. Koo J.S., Jung W., Jeong J. Metastatic breast cancer shows different immunohistochemical phenotype according to metastatic site. Tumori 2010, 96:424-432.
45. Broom R.J., Tang P.A., Simmons C., et al. Changes in estrogen receptor, progesterone receptor and Her-2/neu status with time: discordance rates between primary and metastatic breast cancer. Anticancer Res 2009, 29:1557-1562.
46. Shimizu C., Fukutomi T., Tsuda H., et al. C-erbB-2 protein overexpression and p53 immunoreaction in primary and recurrent breast cancer tissues. J Surg Oncol 2000, 73:17-20.
47. Idirisinghe P.K., Thike A.A., Cheok P.Y., et al. Hormone receptor and c-ERBB2 status in distant metastatic and locally recurrent breast cancer. Pathologic correlations and clinical significance. Am J Clin Pathol 2010, 133:416-429.
48. D'Andrea M.R., Limiti M.R., Bari M., et al. Correlation between genetic and biological aspects in primary non-metastatic breast cancers and corresponding synchronous axillary lymph node metastasis. Breast Cancer Res Treat 2007, 101:279-284.
49. Azam M., Qureshi A., Mansoor S. Comparison of estrogen receptors, progesterone receptors and HER-2/neu expression between primary and metastatic breast carcinoma. J Pak Med Assoc 2009, 59:736-740.
50. Aitken S.J., Thomas J.S., Langdon S.P., et al. Quantitative analysis of changes in ER, PR and HER2 expression in primary breast cancer and paired nodal metastases. Ann Oncol 2010, 21:1254-1261.
51. Amir E., Clemons M., Purdie C.A., et al. Tissue confirmation of disease recurrence in breast cancer patients: pooled analysis of multi-centre, multi-disciplinary prospective studies. Cancer Treat Rev 2012, 38:708-714.
52. Gancberg D., Di Leo A., Cardoso F., et al. Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites. Ann Oncol 2002, 13:1036-1043.
53. Pestrin M., Bessi S., Puglisi F., et al. Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept study. Breast Cancer Res Treat 2012, 134(1):283-289.
54. Meng S., Tripathy D., Shete S., et al. HER-2 gene amplification can be acquired as breast cancer progresses. Proc Natl Acad Sci USA 2004, 101:9393-9398.